REVIVA PHARMACEUTICALS HOLDINGS, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 10080 N WOLFE ROAD, CUPERTINO, CA, 95014
Mailing Address 10080 N WOLFE ROAD, CUPERTINO, CA, 95014
Phone 4085018881
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
$8.39M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | January 23, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 16, 2026 | View on SEC |
| 8-K Current report of material events | December 23, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | December 22, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
Material Events
8-K Financial Distress January 23, 2026
High Impact
- Secured a critical Nasdaq listing extension until March 27, 2025, providing a temporary reprieve from delisting.
- The extension mitigates immediate severe negative financial consequences associated with delisting, preserving visibility, liquidity, credibility, and capital access.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.